[ORGANIZATION]
Rinvoq
Featured in 6 tracked stories · first seen
Situations
AbbVie financial performance and strategic transition
2 clusters · 8 sources · last updated
Latest: AbbVie raises profit guidance following strong Q3 results
AbbVie is undergoing a strategic shift in its pharmaceutical focus, moving from its legacy product Humira toward new immunology and oncology treatments. In fiscal year 2025, the company reported revenue of $61.2 billion,
Also covered in
-
AbbVie’s Rinvoq approved for severe alopecia areata in South Korea
[HEALTH] · 2 sources ·